1 not yet recruiting, 1 recruiting, 1 withdrawn. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow S-531011: new trials by email Literature Review of S-531011 trials Research Report on S-531011
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal Cancer S-531011, HD-XRT - Phase II, S-531011 | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2026-08-12 | 2026-09-11 | |
| A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer S-531011, Fruquintinib, Pembrolizumab - Metastatic Colorectal Neoplasms, Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | National Cancer Center Hospital East | 68 | 2026-05-01 | 2026-05-18 |
| S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors S-531011, Pembrolizumab, Bevacizumab - Solid Tumors | Phase 1 / Phase 2 | Recruiting | Shionogi | 282 | 2022-05-30 | 2026-03-18 |
M.D. Anderson Cancer Center (1) · National Cancer Center Hospital East (1) · Shionogi (1)
Japan (1) · United States (1)